Business
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral
About this update from Pulmatrix, Inc.
[{"type":"text","content":"Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole\nPulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma\nBEDFORD, Mass., Aug. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology. PUR1900 is an orally inhaled dry powder formulation of the antifungal itraconazole, utilizing iSPERSE technology, being developed for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma.\n\n \n \n \n \n \n \n\n \nAdministration of PUR1900 results in high lung and low systemic itraconazole exposure. Oral itraconazole is a potent inhibitor of cytochrome P450 3A4 (CYP3A4), which alters the metabolism and consequently the plasma concentrations of other drugs metabolized by this pathway. Co-administration of some of these drugs with oral itraconazole is contraindicated due to the potential for drug-drug interactions (DDI).\nPulmatrix today announced publication of \"Evaluation of the Potential for Drug‑Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data\" in the peer-reviewed American Association of Pharmaceutical Scientists (AAPS) Journal.\nDr. Margaret Wasilewski, Chief Medical Officer of Pulmatrix, commented, \"We are pleased to publish the drug-drug interaction modeling study on PUR1900 in the AAPS Journal. This study demonstrates the risk of DDI with PUR1900 (inhaled itraconazole) is lower than with oral itraconazole and PUR1900 may be safely administered even in patients taking drugs contraindicated with oral itraconazole.\"\nTed Raad, Chief Executive Officer of Pulmatrix, commented, \"While oral itraconazole is part of the standard of care for patients suffering from ABPA, its use is limited due to the side effects and drug to drug interactions associated with the high itraconazole plasma concentrations of oral itraconazole therapy. PUR1900 has the potential to provide an inhalation alternative to oral antifungal therapy in treating ABPA.\" \nPulmatrix is conducting a Phase 2 study ...